Gene
NRG1
NRG1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (20), Actionable biomarkers (2), Trial mentions (45), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NRG1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 4 of 8,738 | 0.05% | not measured | |
| 2025 | 4 of 8,875 | 0.05% | not measured | |
| 2024 | 3 of 8,597 | 0.03% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 11 of 11,460 | 0.10% |
| 2022 | 4 of 8,285 | 0.05% | 14 of 13,598 | 0.10% |
| 2021 | 3 of 8,692 | 0.03% | 15 of 15,045 | 0.10% |
| 2020 | 4 of 7,640 | 0.05% | 9 of 14,459 | 0.06% |
| 2019 | 1 of 7,300 | 0.01% | 15 of 12,159 | 0.12% |
| 2018 | 2 of 6,927 | 0.03% | 12 of 11,854 | 0.10% |
| 2017 | 1 of 6,558 | 0.02% | 16 of 11,595 | 0.14% |
Showing 10 of 37 years.
Assay-provider ledger (20)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina, San Diego, CA, USA | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | June 01, 2017 |
| AVEO Pharmaceuticals, Inc. | Pharma or other | Clinical validation | 1 | March 01, 2015 |
| Covance Central Laboratory Services | Unclassified | Clinical validationAnalytical validation | 1 | March 01, 2015 |
| Daiichi Sankyo | Pharma or other | Clinical validationAnalytical validation | 1 | March 01, 2015 |
| Intertek Pharmaceutical Services | Pharma or other | Clinical validationAnalytical validation | 1 | March 01, 2015 |
Showing 5 of 20 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| NRG1 fusion | AFATINIB | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| NRG1 fusion | LAPATINIB | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (45)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00937443 | Trial biospecimen (AACT) |
| NCT05781308 | Trial eligibility (AACT) |
| NCT01097460 | Trial eligibility (AACT) |
| NCT07110883 | Trial eligibility (AACT) |
| NCT06998940 | Trial eligibility (AACT) |
Showing 5 of 45 trial mentions.
Target-disease associations (535)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ATTRV122I amyloidosis | cardiovascular disease | Mouse knockout (IMPC) |
| Abnormal nasolacrimal system morphology | phenotype | GWAS credible sets |
| Abnormality of the immune system | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Abruptio Placentae | pregnancy or perinatal disease | GWAS credible sets |
Showing 5 of 535 associations.
Vendor sourcing (110)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.233A>T (p.N78I) alteration is located in exon 2 (coding exon 2) of the NRG1 gene. This alteration results from a A to T substitution at nucleotide posi... | View ClinVar record SCV003705672.2 |
| Astellas Pharma Global Development, Inc. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | for CNS metastases); participant must have recovered from all radiotherapy related toxicity to ≤ grade 1, with the exception of alopecia (any grade of alopec... | View trial NCT07566052 |
| Astellas Pharma Global Development, Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | NRG1 | View trial NCT07566052 |
| Baohui Han | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Aged 18 and above, male or female 2. Pathologically diagnosed with advanced or metastatic inoperable non-small cell lung cancer 3. Prior genetic testin... | View trial NCT06846762 |
| Baohui Han | Trial sponsor | Mentioned in trial textTrial free-text mention | NRG1 | View trial NCT06846762 |
Showing 5 of 110 sourcing records.
Trial-cited literature (164)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer. | The New England journal of medicine | 2025 | 103 |
| CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions. | JCO precision oncology | 2025 | 4 |
| Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction. | JACC. Basic to translational science | 2025 | 4 |
| Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. | Circulation. Heart failure | 2025 | 3 |
| Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib. | ESMO open | 2025 | 0 |
Showing 5 of 164 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.M289T | 1 | 2011 | PMID 23429840 |
| p.R38Q | 1 | 2011 | PMID 23429840 |
Literature-extracted relations (52)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| AFATINIB | Chemical | associate |
<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <i>KRAS</i> Wild-Type Pancreatic Ductal Adenocarcinoma. | 2019 |
| Carcinoma, Non-Small-Cell Lung | Disease | associate |
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions. | 2025 |
| Diarrhea | Disease | associate |
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions. | 2025 |
| Nausea | Disease | associate |
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions. | 2025 |
| Neoplasms | Disease | associate |
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions. | 2025 |
Showing 5 of 52 relation assertions.
Organizations publishing (242)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 7 | 2017 to 2025 |
| Mass General Brigham | Hospital | 6 | 2009 to 2025 |
| The University of Texas System | Academic | 6 | 2009 to 2025 |
| Dana-Farber Cancer Institute | Other | 5 | 2014 to 2025 |
| University of Minnesota System | Academic | 5 | 2014 to 2023 |
Showing 5 of 242 organizations.
Where NRG1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- respiratory or thoracic disease
- urinary system disease
497 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.